Evidence map›Paper›PMID 25315420›Full record

ReviewAnnals of the New York Academy of Sciences2015

Autoimmune encephalopathies.

Frank Leypoldt, Thaís Armangue, Josep Dalmau

Open access · greenAbstract readReview
In one paragraph

Review in Annals of the New York Academy of Sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 162 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
162citing papers in PubMed, 1 pooled it
28.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

162 citing papers in PubMed, 1 synthesis or guideline pooled it, 417 citations in OpenAlex.

  1. BrainEuropean journal of nuclear medicine and molecular imaging · 2021
    Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Imaging biomarkers in antibody-mediated autoimmune encephalitis.Quantitative imaging in medicine and surgery · 2025
    Article
  11. Article
  12. Article
  13. Brain sciences · 2025
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

102 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 4 countries.

Frank LeypoldtService of Neurology, Hospital Clinic, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Barcelona, Spain; Institute of Clinical Chemistry, Neuroimmunology Unit and Department of Neurology, University Medical Center Schleswig-Holstein Campus, Kiel, Germany.
Thaís Armangue
Josep Dalmau
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESInstitute of Neuroimmunology of the Slovak Academy of Sciences · SKUniversitat de Barcelona · ES

Funding

Paraneoplastic Disorders of the CNS: Autoantigen ProfilingR01NS077851 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI DALMAU, JOSEP O. · 2011 to 2015
$1.9M
Autoimmunity Against Novel Antigens in Neuropsychiatric DysfunctionR01MH094741 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI BALICE-GORDON, RITA J., DALMAU, JOSEP O. · 2011 to 2014
$1.3M
Synaptic autoimmunity in disorders of memory, behavior, cognition and psychosisRC1NS068204 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI BALICE-GORDON, RITA J., DALMAU, JOSEP O. · 2009 to 2010
$965k
NIMH NIH HHS R01 MH094741NINDS NIH HHS R01 NS077851NINDS NIH HHS RC1 NS068204
6 · The paper itself

Abstract

Over the past 10 years, the continual discovery of novel forms of encephalitis associated with antibodies to cell-surface or synaptic proteins has changed the paradigms for diagnosing and treating disorders that were previously unknown or mischaracterized. We review here the process of discovery, the symptoms, and the target antigens of 11 autoimmune encephalitic disorders, grouped by syndromes and approached from a clinical perspective. Anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis, several subtypes of limbic encephalitis, stiff-person spectrum disorders, and other autoimmune encephalitides that result in psychosis, seizures, or abnormal movements are described in detail. We include a novel encephalopathy with prominent sleep dysfunction that provides an intriguing link between chronic neurodegeneration and cell-surface autoimmunity (IgLON5). Some of the caveats of limited serum testing are outlined. In addition, we review the underlying cellular and synaptic mechanisms that for some disorders confirm the antibody pathogenicity. The multidisciplinary impact of autoimmune encephalitis has been expanded recently by the discovery that herpes simplex encephalitis is a robust trigger of synaptic autoimmunity, and that some patients may develop overlapping syndromes, including anti-NMDAR encephalitis and neuromyelitis optica or other demyelinating diseases.

Indexed as

AutoantibodiesAutoantigensAutoimmune DiseasesEncephalitisHumansReceptors, N-Methyl-D-AspartateAutoantibodiesAutoantigensReceptors, N-Methyl-D-Aspartateanti-NMDAR antibodiesautoimmune encephalitislimbic encephalitispsychosistreatment

Identifiers

PMID25315420
PMCPMC4363225
OpenAlexW2321381259

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.